Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct;25(4):E53-E56.
doi: 10.1111/hdi.12963. Epub 2021 Jul 6.

One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19

Gaetano Alfano  1   2   3 , Francesco Fontana  2 , Niccolò Morisi  1 , Francesco Giaroni  1 , Giacomo Mori  2 , Giovanni Guaraldi  4 , Riccardo Magistroni  1   2 , Gianni Cappelli  1   2 ; Modena Covid-19 Working Group (MoCo19)
Collaborators, Affiliations
Case Reports

One-year persistence of neutralizing anti-SARS-CoV-2 antibodies in dialysis patients recovered from COVID-19

Gaetano Alfano et al. Hemodial Int. 2021 Oct.

Abstract

The immunological mechanisms that modulate immune response to SARS-CoV-2 infection remain elusive. Little is known on the magnitude and the durability of antibody response against COVID-19. There is consensus that patients with immune dysfunction, such as dialysis patients, may be unable to mount a robust and durable humoral immunity after infections. Recent studies showed that dialysis patients seroconverted after COVID-19, but data on the durability of the immune response are missing. We reported the data of a durable anti-spike protein seroconversion after natural SARS-CoV-2 infection in three patients on hemodialysis with a mean age of 67.2 ± 13.8 years. A mean antibody titer of 212.6 ± 174.9 UA/ml (Liaison®, DiaSorin) was found after one year (range, 366-374 days) from the diagnosis of COVID-19. In conclusion, this case series provided evidence that patients receiving hemodialysis who recovered from severe COVID-19 were able to mount a long-lasting immune response against SARS-CoV-2. Although the protective capacity of this long-term immunity remains to be determined, these patients did not report signs of reinfection after recovery from COVID-19.

Keywords: COVID-19; Sars-CoV-2; antibody; dialysis; immunity; vaccine.

PubMed Disclaimer

Conflict of interest statement

All the authors declared no competing interest.

References

    1. Danese MD, Griffiths RI, Dylan M, Yu H‐T, Dubois R, Nissenson AR. Mortality differences among organisms causing septicemia in hemodialysis patients. Hemodial Int. 2006;10:56–62. 10.1111/j.1542-4758.2006.01175.x - DOI - PubMed
    1. Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. Am J Kidney Dis Off J Natl Kidney Found. 2020;75:417–25. 10.1053/j.ajkd.2019.06.014 - DOI - PubMed
    1. McCafferty K, Davari M, Price K, Rajakariar R, Cove‐Smith A, Forbes SH. COVID‐19 prevalence and seroconversion in an urban hemodialysis unit in the United Kingdom. Hemodial Int. 2021;25:137–9. 10.1111/hdi.12883 - DOI - PubMed
    1. Forbes S, Davari M, Gnanasampanthan S, Roth N, Young G, Rajakariar R, et al. Persistence of antibody response to SARS‐CoV‐2 in a cohort of haemodialysis patients with COVID‐19. Nephrol Dial Transplant. 2021;gfab066 10.1093/ndt/gfab066 - DOI - PMC - PubMed
    1. Alcázar‐Arroyo R, Portolés J, López‐Sánchez P, Zalamea F, Furaz K, Méndez Á, et al. Rapid decline of anti‐SARS‐COV‐2 antibodies in patients on hemodialysis. The COVID‐FRIAT study. Clin Kidney J. 2021;sfab048. 10.1093/ckj/sfab048 - DOI - PMC - PubMed

Publication types

Substances